Keele Research Repository
Explore the Repository
Jenkins, SI, Pickard, MR, Khong, M, Smith, HL, Mann, CL, Emes, RD and Chari, DM (2014) Identifying the cellular targets of drug action in the central nervous system following corticosteroid therapy. ACS Chemical Neuroscience, 5 (1). 51 -63. ISSN 1948-7193
ACSChemicalNeuroscience2013.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial.
Download (1MB) | Preview
Abstract
Corticosteroid (CS) therapy is used widely in the treatment of a range of pathologies, but can delay production of myelin, the insulating sheath around central nervous system nerve fibers. The cellular targets of CS action are not fully understood, that is, "direct" action on cells involved in myelin genesis [oligodendrocytes and their progenitors the oligodendrocyte precursor cells (OPCs)] versus "indirect" action on other neural cells. We evaluated the effects of the widely used CS dexamethasone (DEX) on purified OPCs and oligodendrocytes, employing complementary histological and transcriptional analyses. Histological assessments showed no DEX effects on OPC proliferation or oligodendrocyte genesis/maturation (key processes underpinning myelin genesis). Immunostaining and RT-PCR analyses show that both cell types express glucocorticoid receptor (GR; the target for DEX action), ruling out receptor expression as a causal factor in the lack of DEX-responsiveness. GRs function as ligand-activated transcription factors, so we simultaneously analyzed DEX-induced transcriptional responses using microarray analyses; these substantiated the histological findings, with limited gene expression changes in DEX-treated OPCs and oligodendrocytes. With identical treatment, microglial cells showed profound and global changes post-DEX addition; an unexpected finding was the identification of the transcription factor Olig1, a master regulator of myelination, as a DEX responsive gene in microglia. Our data indicate that CS-induced myelination delays are unlikely to be due to direct drug action on OPCs or oligodendrocytes, and may occur secondary to alterations in other neural cells, such as the immune component. To the best of our knowledge, this is the first comparative molecular and cellular analysis of CS effects in glial cells, to investigate the targets of this major class of anti-inflammatory drugs as a basis for myelination deficits.
Item Type: | Article |
---|---|
Additional Information: | This is the accepted author manuscript (AAM). The final published version (version of record) is available online via the American Chemical Society at http://pubs.acs.org/doi/abs/10.1021/cn400167n. Please refer to any applicable terms of use of the publisher. |
Uncontrolled Keywords: | cerebral cortex, microglia, oligodendroglia, cells, cultured, stem cells, animals, animals, newborn, humans, rats, rats, sprague-dawley, dexamethasone, adrenal cortex hormones, gangliosides, antigens, cd11b, nerve tissue proteins, receptors, glucocorticoid, cell proliferation, gene expression regulation, basic helix-loop-helix transcription factors |
Subjects: | R Medicine > R Medicine (General) |
Divisions: | Faculty of Medicine and Health Sciences > Institute for Science and Technology in Medicine |
Related URLs: | |
Depositing User: | Symplectic |
Date Deposited: | 25 Oct 2016 09:02 |
Last Modified: | 25 Oct 2016 09:04 |
URI: | https://eprints.keele.ac.uk/id/eprint/2335 |